

Maurice Dalton

Sept 28/08

- ER IPR +ve patients who may be false negatives
- Issue in testing at HSC since 1997
 - process in St. Johns (this is problem)
 - we would read whether positive or negative

Negative was < 30% - ~~up until~~

Since 2001 < 10% called negative

Across country negative is anything from 0-30%

HCCST changed process in 2004 with new system
+ since August 2007 everything St. John + eh is sent back

- Identified that had issue in false negative
- + trying to get volume of problem.
- 40 mastectomy /yr. 30% will be positive
~ 10 negative.

approximately 70 cases over this time

? minister going nuclear soon

- We are sending all negatives as defined by HCCST to them which are then sending all of these specimens to mainland. At present suggest the false negative rate is 10-20% $\rightarrow \therefore \approx 7-14$ people potentially affected.

Our % +ve has stayed within generally accepted reference levels.

- We will be compiling two lists -
specimens. of 1997-01 to send to
2002 to 2004. St John's.

- They will be reviewing all the outside lab
as well as tracking patient outcomes. Will
have outside laboratory - retest with todays
standards

Susan Bennett

Oct 3/05

- Not doing a press release
- ~~<10%~~ of Breast Ca patients would be effected.
- when story broke on Friday was actually thought to mammography related.
- Dr Williams did NTV interview + is doing Telegram. - based on premise that retested one patient who was negative + became positive. This led to further testing
- Info: This has ~~to be~~ individualized because of various treatment options based on no. of factors.
- media not interested in this story yet.
- Will post on website - few frequently asked questions along w/ patient liaison officer.
- 25% of patients who are negative will change to positive.

Larry Gallagher	-	<u>62</u>	-	<u>150</u>	-	ER/PR Neg Alive Not treated
Maine Dalton	=	<u>88</u>	=		=	

ER/PR Testing

Oct 4/05

- Those who would be positive without any further testing hard or changing criteria
- Those who were negative - 0-1% + may now be positive
- 70-80% breast cancer ER/PR positive but also present in normal breast tissue (
- Prior to 2001 need to be $> 30\%$ true for transition
- After 2001 $> 10\%$ positive
- most labs $\approx 1\%$ negative to be considered negative
- Prior 1997 biochemical markers used
1997 stained immunohistochemistry \rightarrow Dako Seno -
 - 40 step process
 - Automated System
- May 2005 Dr Laing - discussed Sloan-Kettering -
re: Lobular Cancer pt who was initially ER/PR Neg (0/0)
+ retested and found to be positive
- Mt Sinai - old certified Lab in London
 - 25-30% converting
 - Chiel Tech - from Mt Sinai has review procedures
 - Pathologist - Also visited
 - Big issue of quality
 - will recommend all slides be read by 2-3 pathologists in St. Johns.

142 specimens back -

1998 < 30% -

~~2001~~ - cutoff < 10%

- All ER Negative / Independent of PR status
- Pt who were PR positive > 30% were treated

Need pathology assistants to prepare specimens

- Need dedicated lab staff doing this immunohistochemistry
- Regional issues = need to ensure collection / preparation done in a standard procedure across this province
 - this would include standardizing formalin

~60 slides to go out from St. Johns to Toronto from CWHC.

= will get report through HCCST from Mt. Sinai

- 327 sent mid August / 142 reported

= good turn around times with new cases

- 360 - cases 1 yr. breast 135 - 97 - MD out of town

147 - 98

360 - 99

370 - 2000

374 - 2001

344 - 2002

386 - 2004

4) Joy McCarthy

Oct 6/07

- Always treated at 10% -
- Letter going out to every family Dr. in Nfld of what to do, from ~~No evidence Paul Gardiner~~ -
- Medical oncologists will be available to talk to GP or see patient but will not be immediate - may be within few months when is fine
- Support calling patients + advising them on list + will recall with results. With letter from Dr Gardiner + accessibility of oncologists.
- Rx will vary from pt to patient depending on time from original diagnosis, node status at time of surgery, present status, etc.
- There is no change in Rx from 2001 ie 10% or more positive of ER/PR however this was both her and Kara's training. American training may have been different so treatment options not necessarily the same.

Robert Williams telephone call
210 tests sent out so far + returned
41 conversions

Oct 7/07

- Letter from Dr Williams to GPs
- Letter from Mr Gardiner to surgeons

HIROC - didn't want to disclose to patients
until we have test results back.

This caused unnecessary worry in Bahrain
last yr when pts contacted before
results available

- will try to arrange teleconference
with CEO's / HIROC to discuss.

Drugs used for R
Femara (Letrozole)
Lupron (Leuproreide)
Suprefact (Buserecin acetate)
Zoladex (Goserelin)
Tamoxifen
Arimidex (Anastrozole)
Arvinostatin (exemestane)

Breast Cancer Pt ER1PR, patient Oct 11/05

Teleconference Oct 11/05

- Verbal + written correspondence
- No. of calls to their line (consumer feedback line) - consistent message (QI people are responsible for that line)
- decided not to respond individually - after discussion with oncologists.
- HIROC discussions - ongoing ~~existing~~ discuss

George - Each region will identify a contact

- That group will decide re frequency of conference calls

at Pilgrim - use HCCSJ web site + consumer line as point of referral

- ~~777-1300~~
- will use global registry
 - Need to look nationally at inconsistencies in ER1PR a from pathology as well as oncology perspective.

777-6500

Nov 28/05

ERI PR

DW

[REDACTED] re: FU.

- 1) Have no answer to my spreadsheet as to who on our list are actually being retested
- 2) Need to know what will be happening with the conversions. My understanding is that a panel consisting of surgical oncologist, medical oncologist x 2 and radiologist will review with communication to FD &/or attending
- 3) Need to know if all patients being retested have been notified of this as my assumption is that ERIHA have taken ownership & would be making this contact
- 4) [REDACTED] will confirm in writing what the process will be

Conference Call re ER/PR

Dec 5/05

Heather Predham, Jenny Gulliver + Kwon

- Criteria - For retesting

Prior to 2001 ER < 30% considered Negative
~~or~~ whatever PR status.

After 2001 ER < 10% considered Negative
whatever PR status

St. Johns

143 - Central West that have been sent
to Toronto

74 - Central East that have been sent
to Toronto

- confirmed that we will match lists
- St. Johns will be contacting all pts being retested
- ~~If ever~~ All will be recontacted once results come back.
- Will be reviewing all converters by panel Dr Joy McCarthy, Kara Lang, Cook, + Kwon.

Asked 2004/05 recently → done on new system.

Heather Predham 777-6126

570-9703

ERI PRDr Robert WilliamsJan 29/06

- Want us to notify patients that are negative - they will be provided. (
- being panelled - all

124 - results sent to Mt. Sinai & back 770-6124
 49 - to be panelled (Lamy review) 570-9703
 40 - negative - we will
 3 - panelled -
 10 - (no results yet or ductal-in-situ)
 22 - deceased

Heather -~~TH - Gander~~

124 - 6 Falls

49 - to be panelled (Lamy review -

40 - Negative - (Lamy to call) -

3 - panelled already

32 - accelerated

10 - DCIS

71 - Gander

27 - panel

19 - Negative

~~20~~

3 - panelled already

20 - deceased

2 - ~~Gander~~ DCIS

ERI PR -Feb 14/04

- 1) - No change
 - call with script
 - notify FP & script
- 2) - Panelled ~~call with script~~
by ERIHA
 - ~~call with script~~
 - ~~notify FP & script + surgeon, oncologist~~
 - FHU & physician to ensure they have gotten letter + have told patient. (Wait one month)
- 3) Deceased - What to do?

-
- Heather Prentiss - OK with using ~~ERIHA~~ script.
- Will send to us.

- If being panelled ERIHA will call
- Heather will send out list of all patients being panelled
- GFW - ~~53~~ ⁵⁷ ~~130~~ being panelled are Ca Clinic pts
- Gender - ~~29131~~ being panelled are Ca Clinic pts

IROC - will talk to Belky re calling

F.V.
ERIPR Tests Teleconference

March 17/04

- Heather Dredham - Letter to ~~physicians~~ ^{patients} for patients being panelled - by Eastern Health
- Some were brought to paneling group however ~~cannot find~~ were deferred based on not having
- Progress note
 - full pathology report
 - consult report on breast pathology
 - current status
- All negatives which are still negative we will be sent script by Eastern Health + we will call patients
- Deceased will be reviewed + panel deceased converted patients

.)

Teleconference - CEO's, medical Directors May 24/07

+ DOHCS - John Abbott, John Kumbhardt, Mona Itaneney

Eastern Health - Dr. Howell, Dr Denis, Heather Poodham
Terry Gulliver.

Western - Ken Jenkins, Paul Wall, RM Community

Labrador - Boyd, Dr. Daskwa

Issue - All FISH Testing was presumed

(John Abbott) to be done in St. Johns since St. Johns restarted however apparently this is not the case. Outside St. Johns apparently all still being sent to Mt Sinai

Terry Gulliver - Only specimens being done in St. Johns are those from

St. Johns

- rest are being sent to Mt Sinai for ERBB/HER2 (all Breast Cancer pt.).

- 300-350 patients being diagnosed ~~per~~ each year in Nfld.

Nestor Denic - doing St. Johns pts. trying to ensure quality assurance is in place & standards are met.

- Mt Sinai would like St. Johns to take over FISH for all province

+ may have to send out for HER2 - not as not up to standard yet with new antibodies.

- need to ensure with all regions that fixation process for preparation of sample is at same standard

(2)

- across the province. Have drafted a recommendation for proper fixation on such tissue + ensure reproducibility - needs to be fixed in < 24 hrs
- have package prepared for each region so that each region understands protocol + ensures that this will be followed.
 - went through validation process for a year by working in facilities in UK and USA to ensure standards ~~are~~ met. By Feb 1/07 were on with this + started processing their own samples again
 - Eastern Health are ready to take over ERIPR testing in next month + will send HUR-II-new for all province to Mt. Sinai until their testing is validated. Also suggest that review all DCIS for province.
 - Nash got into issue of remuneration of pathologists for taking on extra workload (reviewing breast ca diagnostics for the province)

Tony - in most St John's would do resection + then send back to region for interpretation. In future would suggest that we send ~~specimens~~ ^{specimens} to St Johns after fixing for ERIPR resection + would also be read in St. Johns

(3)

Nanice Do Hon - ND issue that we are aware of related to fixation

Nash Denice - Fixation was a problem at all sites after review

Kerry - Why wasn't this identified before

Terry - If tissue was overfixed may cause issues w/ antigen / antibody + there is new information (? what year) around this that will be shared. (This is part of quality improvement)

- technological advances have helped w/ over/under fixation issues.

Nash - New studies have suggested that maybe fixation with new technologies is not as much an issue. We however have recommendations from world renowned pathologist in this area who suggest we need to improve fixing / processing

Oscar - There is a standardization - with a package - around fixation that has come as part of quality improvement around this issue reviews

(4)

Terry - when a pathologist who was responsible for this left, the reporting of the slides were decentralized - wish to centralize that processing and interpretation again.

Oscar - Data analysis was not done on a regional basis.

- Other than fixation - subsequently reading all other processes were done at HCCST.

Paul Nash - Dec. 2000 changed from 30% to 10% however 1-10% were called low expressors. In USA about 21 people were testing at 10% others may treat 1-10% depending on other factors.

- Technology has changed
- what is positive has changed
- There are process issues which we need to improve
- Issues around fixation - new studies

127